Adam Raben
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adam Raben has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Abhirup Sarkar
3 shared publicationsAlexandra Hanlon
2 shared publicationsAndrew Glick
2 shared publicationsArnold Grebler
2 shared publicationsBruce Benge
2 shared publicationsCharles J. Schneider
Department of Medical Oncology, Helen F. Graham Cancer Center, Christiana Care Health System, Newark, DE, United States
2 shared publications
Latest Publications
- 1 March 2018
- Published by Elsevier in Oral Oncology
- Vol. 78, 102-107
Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis
- 1 March 2018
- Published by Elsevier in Oral Oncology
- Vol. 78, 102-107
Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: A propensity score analysis
- 1 July 2017
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 26 (3)
Update of Practical Radiation Oncology Management Trends for Surgeons
- 1 July 2017
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 26 (3)
Update of Practical Radiation Oncology Management Trends for Surgeons
- 1 May 2017
- Published by Elsevier in Brachytherapy
- Vol. 16 (3) , 490-496
Biochemical control and toxicity for favorable- and intermediate-risk patients using real-time intraoperative inverse optimization prostate seed implant: Less is more!
- 1 May 2017
- Published by Elsevier in Brachytherapy
- Vol. 16 (3) , 490-496
Biochemical control and toxicity for favorable- and intermediate-risk patients using real-time intraoperative inverse optimization prostate seed implant: Less is more!
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16614
Minimizing urinary toxicity in daily prostate stereotactic body radiotherapy with urethra dose constraints.
E16614 Background: Stereotactic body radiotherapy (SBRT) is an evolving and promising treatment modality for prostate cancer but without mature data compared with other definitive therapies. There is currently no standard dose fractionation or timing for prostate SBRT. Prior preliminary data indicate that daily treatment is toxic and every other day (QOD) treatment is safer. However, some patients prefer daily treatments to decrease overall treatment time and travel expenses. We challenged the hypothesis that daily treatment is toxic and provide prospective data of daily SBRT treatment. Methods: 21 patients with localized prostate cancer were prospectively treated at our institution from 2009 to 2015 with SBRT using CyberKnife. Treatment consisted of 36.25 Gy in 5 daily fractions with prostatic and membranous urethra dose constraints (V47 < 20% and D50 < 37Gy, respectively) and daily dexamethasone. Patient reported bladder and rectal toxicity was graded on the Radiation Therapy Oncology Group scale. Baseline and post-treatment international prostate symptom score (IPSS), sexual health inventory for men (SHIM), urinary symptom quality of life (QOL) and PSA levels were compared using McNemar’s Chi’square and Bowker tests. Results: Median follow-up was 24 months. At last follow-up, 8, 5 and 4 patients had grade 1 and 2 urinary, and grade 1 rectal toxicity, respectively. No grade 3 toxicity was observed. There were no statistically significant differences in baseline and post-treatment IPSS, SHIM and urinary QOL scores. Median PSA at follow-up was 0.7 ± 1.1 ng/mL. No patients had biochemical recurrence by Phoenix criteria. Conclusions: The toxicity profile of QOD treatment compared favorably with historical data; grade 3 toxicity as reported in prior daily SBRT studies was not observed. Biochemical failure free survival compared favorably with other definitive treatment modalities. These data indicate that daily SBRT with urethra dose constraints for localized prostate cancer may result in a comparable toxicity profile to that of QOD treatment, decrease overall days of treatment duration and associated travel costs.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16614
Minimizing urinary toxicity in daily prostate stereotactic body radiotherapy with urethra dose constraints.
E16614 Background: Stereotactic body radiotherapy (SBRT) is an evolving and promising treatment modality for prostate cancer but without mature data compared with other definitive therapies. There is currently no standard dose fractionation or timing for prostate SBRT. Prior preliminary data indicate that daily treatment is toxic and every other day (QOD) treatment is safer. However, some patients prefer daily treatments to decrease overall treatment time and travel expenses. We challenged the hypothesis that daily treatment is toxic and provide prospective data of daily SBRT treatment. Methods: 21 patients with localized prostate cancer were prospectively treated at our institution from 2009 to 2015 with SBRT using CyberKnife. Treatment consisted of 36.25 Gy in 5 daily fractions with prostatic and membranous urethra dose constraints (V47 < 20% and D50 < 37Gy, respectively) and daily dexamethasone. Patient reported bladder and rectal toxicity was graded on the Radiation Therapy Oncology Group scale. Baseline and post-treatment international prostate symptom score (IPSS), sexual health inventory for men (SHIM), urinary symptom quality of life (QOL) and PSA levels were compared using McNemar’s Chi’square and Bowker tests. Results: Median follow-up was 24 months. At last follow-up, 8, 5 and 4 patients had grade 1 and 2 urinary, and grade 1 rectal toxicity, respectively. No grade 3 toxicity was observed. There were no statistically significant differences in baseline and post-treatment IPSS, SHIM and urinary QOL scores. Median PSA at follow-up was 0.7 ± 1.1 ng/mL. No patients had biochemical recurrence by Phoenix criteria. Conclusions: The toxicity profile of QOD treatment compared favorably with historical data; grade 3 toxicity as reported in prior daily SBRT studies was not observed. Biochemical failure free survival compared favorably with other definitive treatment modalities. These data indicate that daily SBRT with urethra dose constraints for localized prostate cancer may result in a comparable toxicity profile to that of QOD treatment, decrease overall days of treatment duration and associated travel costs.
- 1 November 2008
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 72 (3) , 820-827
Anatomy-Based Inverse Planning Simulated Annealing Optimization in High-Dose-Rate Prostate Brachytherapy: Significant Dosimetric Advantage Over Other Optimization Techniques
- 1 November 2008
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 72 (3) , 820-827
Anatomy-Based Inverse Planning Simulated Annealing Optimization in High-Dose-Rate Prostate Brachytherapy: Significant Dosimetric Advantage Over Other Optimization Techniques
- 1 December 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 60 (5) , 1631-1638
Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose
- 1 December 2004
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 60 (5) , 1631-1638
Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose
- 1 December 2003
- Vol. 75 (12) , 455-9
Head and neck cancer care in Delaware: the advent of the Helen F. Graham Head and Neck Multi-Disciplinary Center.
- 1 December 2003
- Vol. 75 (12) , 455-9
Head and neck cancer care in Delaware: the advent of the Helen F. Graham Head and Neck Multi-Disciplinary Center.